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Abstract
Background: Preterm infants are at risk for neurodevelopmental sequelae even in absence of major cerebral lesions.
The hypothesis that Human Recombinant Erythropoietin (rEpo) could improve the neurodevelopmental outcome in
risk neonates has raised the highest interest in recent years.
Methods: A group of preterm neonates born at a gestational age≤ 30 weeks and free from major cerebral lesions or
major visual impairment, were included in the study if they had a complete neurologic evaluation for at least 24 months
of postmenstrual age. They were assigned to group I in the case they had been treated with rEpo or group II if untreated.
The aim was to evaluate whether rEpo, given at the high cumulative doses utilized for hematologic purposes, is
able to improve the neurodevelopmental outcome in preterm infants born at a gestational age ≤ 30 weeks. A
group of 104 preterm neonates were studied: 59 neonates who received rEpo for 6.9 ± 2.4 weeks at a median cumulative
dose of 6300 UI/Kg (6337 ± 2434 UI/Kg), starting at a median age of 4 days and 45 neonates who were born in the
period preceding the routine use of rEpo. The neurodevelopmental quotient at 24 month postmenstrual age was
assessed utilizing the Griffiths’ Mental Developmental Scales.
Results: Our results failed to show any difference in the Developmental Quotient at 24 month. Bronchopulmonary
dysplasia, minor intraventricular hemorrhages and blood transfusions were the clinical features significantly related to the
Developmental Quotient.
Conclusions: Our results do not support the hypothesis that rEpo, administered with the schedule utilized for
hematologic purposes, improve the neurodevelopmental outcome of preterm neonates, at least those preterm infants
free from major impairments.
Background
Preterm infants are recognized to be at risk for neurode-
velopmental (ND) sequelae even in absence of major
cerebral lesions. The abnormal milieu of preterm extra-
uterine life, in particular ischaemia and inflammation,
make preterm infants susceptible to cerebral injury po-
tentially leading to ND sequelae even in absence of
major cerebral lesions [1]. Animal studies using a variety
of models for hypoxic-ischemic brain injury, as well as a
clinical trial on adult humans who had sustained a brain
stroke, provided substantial evidence for significant neu-
roprotective effects of rEpo [2–4]. As a consequence, the
hypothesis that rEpo could improve the ND outcome in
risk neonates has raised the highest interest in recent
years [5–7]. Its neurotrophic, anti-inflammatory, anti-
apoptotic, angiogenic, anti-oxidant and anti-epileptic
properties have been investigated over the last decade
and its underlying mechanisms in terms of signal trans-
duction pathways have been defined [8–18]. Experimen-
tal studies have evaluated the neuroprotective effects of
high intravenous doses of rEpo given as a fast bolus, but
recent retrospective clinical studies have investigated the
hypothesis that the high cumulative doses utilized to
prevent the anaemia of prematurity might be neuropro-
tective in preterm infants as well. Conflicting results
have been reported. [19–23].
The aim of the present study is to evaluate whether
rEpo, given at the high cumulative doses utilized for
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hematologic purposes, has improved the ND outcome in
a series of preterm neonates free from major cerebral
lesions or major visual impairment compared with a
series of untreated neonates born at similar GA. Second-
arily, the clinical variables potentially influencing the
outcome have been investigated as well.
Methods
Patients
Charts of all preterm infants born at a GA ≤ 30 weeks
and admitted to the neonatal intensive care unit of the
A. Gemelli University Hospital in Rome from 12.1.2002
to 1.31.2007 were retrospectively evaluated. Infants
with congenital anomalies or major neurological and
sensory impairments (cerebral palsy, deafness, retinopathy
of prematurity stage >2) as well as infants affected by
major intracranial lesions, i.e. extensive subependymal-
intraventricular hemorrhage (SEH-IVH Grade III-IV) [24],
periventricular infarction, periventricular leucomalacia
and post-hemorrhagic hydrocephalus or severe ventricular
dilation, were excluded from the study. The occurrence of
minor SEH-IVH (Grade I-II) [24] was not considered
among the exclusion criteria. Serial ultrasound evaluations
(at least three times during the first week of life and
weekly thereafter until discharge) were performed using a
Hewlett-Packard Image Point equipped with a multifre-
quency beam [5–7,5 MHz). Diagnosis of bronchopulmon-
ary dysplasia (BPD) included O2 dependency at 36 week
postmenstrual age (PMA) and / or more than 28 days of
oxygen therapy [25]. No major changes in clinical care
were introduced during the study period. Two groups of
neonates were considered: the study group (G1) includes
neonates born between December 2004 and January 2007
who received rEpo for preventing the anaemia of pre-
maturity; the control group (G2) includes neonates born
during the 2 years before the protocol for prevention of
anaemia was started. Approval for the study was obtained
by the Ethical Commettee of Gemelli University Hospital.
rEpo therapy
A dose of 300 UI/kg 3 times per week was administered
subcutaneously or intravenously in 24 h until central
venous line was removed and then subcutaneously [26].
The rEpo was started before the 14th day of life and con-
tinued through the 35th week PMA [27] unless adverse
effects were observed.
Follow-up
All infants have been regularly followed for at least
24 months PMA with a standardized neurological and
ND assessment. Neurological examination consisted of a
structured assessment evaluating cranial nerve function,
posture, movements, tone, reflexes/saving reactions and
visual behaviour [28].
ND assessment at 24 month PMA was performed util-
izing the Griffiths’ Mental Developmental Scales [29].
The assessment includes motor, personal and social,
language, hand and eye and performance scales. ND was
classified as: normal, when developmental quotient (DQ)
was > 85; borderline, when DQ was between 70 and 85;
delayed when DQ was less than 70. Neurological exam-
ination as well as ND assessment was always performed
by trained pediatric neurologists.
Statistical analyses
The data are reported as mean ± standard deviation or
count and percent according to variables nature (continu-
ous or count/categorical). The study population has been
divided in two groups according to the rEpo administra-
tion. The differences between groups were evaluated by
the Wilcoxon rank sum test (Mann Whitney U test) or the
Student's t-test as appropriate according to nonparametric/
parametric distribution for the continuous variables; cate-
gorical data were analyzed by Fisher’s exact test.
The association between the studied variables and the
DQ has been investigated by Pearson’s correlation for con-
tinuous variables (r for significant associated variables
have been reported) or the Wilcoxon rank sum test/stu-
dent’s t-test for the binary ones. Linear regression has
been used to adjust the significant associations found for
birth weight (BW) or GA; GA and BW were collinear, so
we cannot put both in the same model. A high grade of
collinearity was found for mechanical ventilation, oxygen
and BPD; we decided to use only the last one in the multi-
variate analysis. When 2 variables described the same risk
(e.g., transfusion number and transfusion requirement),
the variables that had the stronger association with the
ND outcome were chosen for multivariate analysis. A two
tailed p < 0.05 was considered significant. Analyses were
performed with Stata/IC 12.
Results
One hundred and four infants were included in the
study. They represented the 87 % of the infant series
from the original data set with complete medical records
and follow-up evaluation once the exclusion criteria
were applied. G1 includes 59 and G2 45 neonates. The
main clinical variables of both groups are described in
Table 1. We found a higher prevalence of surfactant
treatment in G1 and a higher percentage of minor SEH-
IVH in G2. Treated infants received rEpo at a median
cumulative dose of 6300 UI/Kg (6337 ± 2434 UI/Kg),
starting at a median age of 4 days (range: 1–13 days).
The median duration of treatment was 6.9 ± 2.4 weeks.
A dose of 300 UI/kg 3 times per week was administered
subcutaneously or intravenously in 24 h. Thirty-five neo-
nates received rEpo intravenously until central venous
line was removed and then subcutaneously, 4 neonates
Luciano et al. Italian Journal of Pediatrics  (2015) 41:64 Page 2 of 6
received rEpo intravenously till the treatment was dis-
continued. rEpo was administered subcutaneously from
the start in 20 neonates. The ND assessment was per-
formed at 24 ± 1 month PMA. The median total DQ
score was 101.0 ± 11.7 for G1 and 108.9 ± 13.0 for G2
(p = 0.538) (Table 2). There is no difference in the
prevalence of total DQ ≤ 85 at 24 month PMA in the
two groups (Table 3). We only found a higher incidence
of DQ ≤ 85 at 24 month PMA in the A Griffiths’ scale
in G2 (p = 0.013). Two neonates in G1 had DQ < 70.
Clinical variables showing significant correlation with
the DQ were number of blood transfusions, lower BW
and GA, hours of oxygen therapy and conventional mech-
anical ventilation (Table 4). When DQ was evaluated ac-
cording to the presence/absence of clinical variables, no
significant difference was found according to surfactant
therapy (DQ respectively 103.9 ± 12.1 and 109.8 ± 14.7 in
Table 1 Main clinical variables in the two studied groups
G1 G2 p
N = 59 N = 45
Female (n - %) 40 – 67.8 22 – 48.9 0.07
Twins (n - %) 12 – 20.3 15 – 33.3 0.176
Gestational age (M ± SD) wk 28.1 ± 1.7 28.3 ± 1.2 0.591
Birth weight (M ± SD) g 1110.8 ± 304.6 1099.8 ± 229.0 0.840
Vaginal delivery (n - %) 7 – 11.9 3 – 6.7 0.508
5’ Apgar score >7 (n - %) 56 – 94.9 42 -93.3 1.000
Prenatal steroid treatment (n - %) 31 – 52.5 26 – 57.8 0.692
Postnatal steroid treatment
n - % 8 – 13.6 6 – 13.3 1.000
M ± SD, d 0.9 ± 2.4 1.9 ± 8.2 0.361
Surfactant treatment (n - %) 56 – 94.9 28 – 62.2 <0.01
CPAP (M ± SD), h 319.4 ± 311.4 274.4 ± 221.4 0.412
Conventional mechanical ventilation, (M ± SD), h 80.7 ± 121.2 60.0 ± 104.4 0.361
HFOV (M ± SD), h 54.8 ± 139.8 22.8 ± 92.7 0.187
O2 therapy (M ± SD), h 281.5 ± 395.1 330.0 ± 443.1 0.558
Inhaled nitric oxide(M ± SD), h 2.8 ± 15.5 3.9 ± 15.5 0.708
Bronchopulmonary dysplasia (n - %) 32 – 54.2 18 – 40.0 0.169
Indomethacin treatment (n - %) 7 – 11.9 1 – 2.2 0.133
Patent ductus arteriosus ligation (n - %) 4 – 6.8 0 – 0.00 0.131
Packed red blood cells transfusions
n - % 36 – 61.0 31 – 68.9 0.535
M ± SD 1.4 ± 1.5 1.4 ± 1.5 0.850
Retinopathy of prematurity grade I-II (n - %) 37 – 62.7 20 – 44.4 0.075
Intracranial hemorrhage grade I-II (n - %) 22 – 37.3 28 – 62.2 0.017
Intracranial hemorrhage grade I (n - %) 6 – 10.2 6 – 13.3 0.759
Intracranial hemorrhage grade II (n - %) 16 – 27.1 22 – 48.9 0.026
Necrotizing enterocolitis (n - %) 1 – 1.7 0 – 0.0 1.000
h hours
Table 2 Developmental quotient (DQ) according to the Griffith
scales in the two studied groups
G1 G2 p
(M ± SD) (M ± SD)
A – loco-motor 105.4 ± 13.9 103.4 ± 13.1 0.453
B – personal-social 112.4 ± 14.7 111.6 ± 18.4 0.816
C – hearing and language 103.1 ± 18.7 96.8 ± 15.3 0.069
D – eye and hand coordination 102.0 ± 12.3 102.6 ± 13.9 0.823
E – performance 105.9 ± 17.1 108.3 ± 16.5 0.480
DQ total 101.0 ± 11.7 108.9 ± 13.0 0.538
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treated and not treated infants p 0.071). On the contrary,
BPD, minor SEH-IVH and requirement of blood transfu-
sion were significantly associated with lower DQ scores
(Table 5). The correlation was still present after adjust-
ment for BW in the case of BPD and minor SEH-IVH and
after adjustment for GA as concerns BPD. A subgroup
analysis for those subgroups showing statistically signifi-
cant differences in DQ was performed. No significant dif-
ference in DQ according to exposure or not to rEpo was
found (Table 6).
Discussion
The brain of preterm infants is highly susceptible to
ischemic and inflammatory insults that may be respon-
sible for ND sequelae even in absence of major cerebral
lesions. Erythropoietin is considered a promising neuro-
protective compound for its known antiinflammatory
and antiapoptotic properties. It is also routinely used in
Neonatology Units for haemathologic purposes. EPO
has been administered in 2 different ways. A previous
study from our group was performed to compare the
two ways of administration. No difference was found in
the hematologic effect [26]. Our results failed to show any
difference in DQ at 24 month PMA between preterm neo-
nates treated or not treated with rEpo given at doses com-
monly administered for preventing the anaemia of
prematurity, whereas we found a significant lower DQ in
neonates affected by minor IVH or BPD and in neonates
who required blood transfusions. Similar results on the
neuroprotective effect of the rEpo treatment utilized for
hematologic purposes were found by the first authors who
tested this hypothesis [19, 20]. Other studies reported a
better cognitive outcome following a higher rEpo dosage
in preterm neonates compared with a lower dosage group
[21, 22]. Bierer et al., who analyzed a small group of 12
preterm infants, observed higher mental developmental
index (MDI) scores in those neonates with serum erythro-
poietin concentrations ≥ 500 mU/mL compared with neo-
nates whose serum concentrations was < 500 mU/mL
[21]. Psycomotor developmental index scores did not dif-
fer between those 2 groups. Following this study, Brown
et al. examined the association between different doses of
rEpo treatment and ND outcomes in a large number of
preterm infants ≤ 30 week GA [22]. They found that
higher 6-week cumulative rEpo doses were associated with
higher MDI scores, consistent with the results reported by
Bierer. An important limitation of this study was that the
final population was only 22 % of the original cohort.
However, the wide range of cumulative rEpo doses in-
cluded in the statistical analysis helped to establish a
dose–response relationship between rEpo doses and ND
outcomes (MDI scores), and it allowed for the hypothesis
of a threshold effect. The rEpo per Kg doses in our popu-
lation were intermediate between the two groups in
Brown’s study, but the treated babies in our series received
a larger cumulative dose than the higher dosage group in
Brown’s study because of a longer duration of treatment.
In 2010, Neubauer et al. investigated the ND outcome at
Table 4 Clinical variables showing significant correlation with
the Developmental Quotient (DQ) (Pearson’s correlation for
continuous variables)
r p
Gestational age 0.2175 <0.05
Birth weight 0.2443 <0.05
Conventional mechanical ventilation, h - 0.2805 <0.01
O2 therapy, h - 0.2130 <0.05
Packed red blood cells transfusions, n - 0.2890 <0.01
h hours
Table 5 Developmental Quotient (DQ) according to the
presence/absence of clinical variables (only clinical variables
showing statistically significant differences are reported)
Present Absent p
(M ± SD) (M ± SD)
Bronchopulmonary
dysplasia
102.9 ± 12.6 109.2 ± 13.3 0.019
Packed red blood cells
transfusions
101.7 ± 11.7 108.9 ± 13.0 0.018
Subependimal-intraventricular
hemorrhage grade I-II
101.8 ± 13.4 108.2 ± 12.3 0.011
Table 6 Subgroup analysis showing Developmental Quotient
(DQ) according to exposure or not to rEpo (only those subgroups
showing statistically significant differences are reported)
rEpo+ rEpo- p
(M ± SD) (M ± SD)
Bronchopulmonary
dysplasia
102.0 ± 9.8 99.2 ± 14.65 0.411
Packed red blood cells
transfusions
104.3 ± 9.7 101.2 ± 15.2 0.312
Subependimal-intraventricular
hemorrhage grade I-II
103.4 ± 11.5 100.5 ± 14.7 0.454
Table 3 Number of neonates with developmental quotient
(DQ) ≤85 in the two studied groups
G1 G2 p
(M ± SD) (M ± SD)
A – loco-motor 0 – 0 5 – 11.1 0.013
B – personal-social 1 – 1.7 3 – 6.7 0.313
C – language 9 – 15.3 6 – 13.3 1.000
D – eye and hand coordination 4 – 6.8 3 – 6.7 1.000
E – performance 6 – 10.2 4 – 8.9 1.000
Total DQ 3 – 5.1 3 – 6.7 1.000
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school age of extremely low birth weight (ELBW) infants
submitted to rEpo treatment in order to stimulate erythro-
poiesis [23]. Analyses of variance (ANOVAs) showed that
rEpo group scored significantly better than untreated chil-
dren. Similar results were obtained when those children
with SEH-IVH were considered, whereas treated and un-
treated children without SEH-IVH did not differ in their
outcome. As a consequence, differences found in the
general population should be credited to children with
SEH-IVH. The results of this observational study support
the hypothesis that rEpo is neuroprotective in ELBW in-
fants with SEH-IVH, but not effective as well in preterm
neonates without cerebral lesions. These findings could
contribute to explain some conflicting results reported in
the different studies and are consistent with our results
obtained in preterm infants not affected by intracranial
lesions. We found a significant lower DQ in neonates
affected by minor IVH or BPD and in neonates who
required blood transfusions. The present study failed to
show a neuroprotective effect of high cumulative doses of
rEpo in preterm infants without major cerebral lesions, at
least for a ND assessment limited to 24 month PMA. The
number of infants considered for the study is limited be-
cause criteria for exclusion were strict in order to elimin-
ate potential bias. Moreover, neonates were not included if
they had not been subjected to a complete neurological
assessment with developmental scales at the correct time.
We are conscious that number of patients is not sufficient
to draw definitive conclusions but our results could be
helpful when regarded together with similar analysis in the
literature.
Since studies dealing with this topic, including the
present one, were not originally designed to examine ND
outcomes, the results should be regarded as preliminary
information for better targeting future investigations.
Conclusions
The present study failed to document a neuroprotective
effect of high cumulative doses of rEpo in PT infants with-
out major cerebral lesions, at least for a ND assessment
limited to 24 month CA. Although the limited number of
patients included in our study do not allow to draw de-
finitive conclusions, our results may be helpful when
regarded together with similar analysis in the literature.
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